Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelgeneBUE:CELG 10 EV-to-EBIT is 13.73 as of Sep. 13, 2026, which is 58% below its 10-year median of 33.00. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Celgene's Enterprise Value is ARS4,605,377.62 Mil.
Celgene's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 was ARS335,469.89 Mil. Therefore, Celgene's EV-to-EBIT for today is 13.73.
The historical rank and industry rank for Celgene's EV-to-EBIT or its related term are showing as below:
BUE:CELG'
s EV-to-EBIT Range Over the Past 10 Years
Min: 29 Med: 33 Max: 41
Current: 1.2
During the past 13 years, the highest EV-to-EBIT of Celgene was 41.00. The lowest was 29.00. And the median was 33.00.
BUE:CELG's EV-to-EBIT is not ranked
in the Drug Manufacturers industry.
Industry Median: 15.77
vs BUE:CELG: 1.20
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Celgene's Enterprise Value for the quarter that ended in Sep. 2019 was ARS0.00 Mil.
Celgene's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS335,469.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celgene EV-to-EBIT Related Terms
Celgene EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Celgene's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:CELG vs GILD, BIIB, ACT: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, Celgene's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celgene EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celgene's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Celgene's EV-to-EBIT falls into.
Celgene's current Enterprise Value is ARS4,605,377.62 Mil.
Celgene's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS335,469.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celgene (BUE:CELG) has a EV-to-EBIT of 13.73 as of Sep. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Celgene and its competitors. This is 58% below median its historical median of 33.00. Over the past decade, Celgene's EV-to-EBIT has ranged from 29.00 to 41.00.
Is Celgene's EV-to-EBIT too high?
Celgene's current EV-to-EBIT of 13.73 is 58% below median its 10-year median of 33.00. Over the past 10 years, this metric has ranged from a low of 29.00 to a high of 41.00. The Drug Manufacturers industry median EV-to-EBIT is 15.77. Celgene's value of 13.73 is 12.9% below this industry median. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's EV-to-EBIT compare to GILD and BIIB?
Celgene's EV-to-EBIT of 13.73 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 15.77. Celgene's value of 13.73 is 12.9% below this benchmark. Historically, Celgene's own EV-to-EBIT has ranged from 29.00 to 41.00 over the past decade. While the company's 10-year median is 33.00 vs. the industry median of 15.77, Celgene has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celgene's current EV-to-EBIT of 13.73 is 12.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Celgene and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celgene's current EV-to-EBIT is 13.73, which is 58% below median its own 10-year median of 33.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current EV-to-EBIT of 13.73. The current EV-to-EBIT is 13.73, which is 58% below median its 10-year median of 33.00 and 12.9% below the Drug Manufacturers industry median of 15.77. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Celgene (BUE:CELG), the current EV-to-EBIT is 13.73 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:CELG has been successfully added to your 
